SPA
CORT icon

Sherbrooke Park Advisers’s Corcept Therapeutics CORT Stock Holding History

Sherbrooke Park Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,984
Closed -$227K – 559
2025
Q1 		$227K Sell
1,984
-3,636
-65% -$221K 0.11% 391
2024
Q4 		$283K Buy
+5,620
New +$294K 0.09% 436

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sherbrooke Park Advisers's CORT Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 1,984 shares — an estimated $227K sold.

Sherbrooke Park Advisers first reported a position in CORT in Q4 2024 and held it in 2 quarters. The position peaked at $283K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 1,984 Corcept Therapeutics shares in Q2 2025, an estimated $227K.
  • Sherbrooke Park Advisers first reported a position in Corcept Therapeutics in Q4 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Corcept Therapeutics position peaked at $283K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.